Table 2.
Antiretroviral drug combination regimens used during the study period
| Regimen | Age, years | Year, n (%)
|
||||||
|---|---|---|---|---|---|---|---|---|
| 2011 (n=53) | 2012 (n=71) | 2013 (n=89) | 2014 (n=115) | 2015 (n=130) | 2016 (n=154) | 2017 (n=160) | ||
|
| ||||||||
| NRTIs/NNRTIs | Total | 9 (17.0) | 11 (15.5) | 8 (9.0) | 13 (11.3) | 11 (8.5) | 23 (14.9) | 8 (5.0) |
| <50 | 5 (9.4) | 6 (8.5) | 3 (3.4) | 5 (4.3) | 4 (3.1) | 11 (7.1) | 3 (1.9) | |
| ≥50 | 4 (7.5) | 5 (7.0) | 5 (5.6) | 8 (7.0) | 7 (5.4) | 12 (7.8) | 5 (3.1) | |
|
| ||||||||
| NRTIs/PIs | Total | 40 (75.5) | 50 (70.4) | 61 (68.5) | 76 (66.1) | 67 (51.5) | 64 (41.6) | 38 (23.8) |
| <50 | 23 (43.4) | 30 (42.3) | 36 (40.5) | 45 (39.1) | 39 (30.0) | 40 (26.0) | 24 (15.0) | |
| ≥50 | 17 (32.1) | 20 (28.2) | 25 (28.1) | 31 (27.0) | 28 (21.5) | 24 (15.6) | 14 (8.8) | |
|
| ||||||||
| NRTIs/INSTIs | Total | – | 7 (9.9) | 17 (19.1) | 23 (20.0) | 45 (34.6) | 59 (38.3) | 106 (66.3) |
| <50 | – | – | 5 (5.6) | 7 (6.1) | 20 (15.4) | 30 (19.5) | 58 (36.3) | |
| ≥50 | – | 7 (9.9) | 12 (13.5) | 16 (13.9) | 25 (19.2) | 29 (18.8) | 48 (30.0) | |
|
| ||||||||
| NRTIs/NNRTIs/PIs | Total | 3 (5.7) | – | – | – | – | – | – |
| <50 | 2 (3.8) | – | – | – | – | – | – | |
| ≥50 | 1 (1.9) | – | – | – | – | – | – | |
|
| ||||||||
| NRTIs/PIs/INSTIs | Total | – | – | 1 (1.1) | 1 (0.9) | 2 (1.5) | 2 (1.3) | 1 (0.6) |
| <50 | – | – | – | – | 1 (0.8) | 1 (0.6) | – | |
| ≥50 | – | – | 1 (1.1) | 1 (0.9) | 1 (0.8) | 1 (0.6) | 1 (0.6) | |
|
| ||||||||
| NRTIs/NNRTIs/INSTIs | Total | – | – | – | – | – | – | 1 (0.6) |
| <50 | – | – | – | – | – | – | – | |
| ≥50 | – | – | – | – | – | – | 1 (0.6) | |
|
| ||||||||
| Non-NRTIs | Total | 1 (1.9) | 3 (4.2) | 2 (2.2) | 2 (1.7) | 5 (3.8) | 6 (3.9) | 6 (3.8) |
| <50 | 1 (1.9) | 2 (2.8) | 2 (2.2) | 2 (1.7) | 3 (2.3) | 3 (1.9) | 3 (1.9) | |
| ≥50 | – | 1 (1.4) | – | – | 2 (1.5) | 3 (1.9) | 3 (1.9) | |
Abbreviations: INSTIs, integrase strand transfer inhibitors; NNRTIs, non-nucleoside reverse transcriptase inhibitors; NRTIs, nucleoside reverse transcriptase inhibitors; PIs, protease inhibitors.